Therapeutic opportunities for muscarinic receptors in the central nervous system.
Felder
C C
CC
Eli Lilly Research Laboratories, Indianapolis, Indiana 46285, USA. felder@lilly.com
Bymaster
F P
FP
Ward
J
J
DeLapp
N
N
D000494:Allosteric Regulation; D000544:Alzheimer Disease / Q000188:drug therapy*; D000818:Animals; D001921:Brain / Q000502:physiology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D018721:Muscarinic Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy*; D015398:Signal Transduction
D002800:Cholinesterase Inhibitors; D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D011976:Receptors, Muscarinic